Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myeloid leukemia (CML) treatment, significantly improving patient survival.
• Imatinib, the first TKI, transformed CML management, allowing it to be treated as a chronic condition.
• Subsequent generations of TKIs (nilotinib, dasatinib, bosutinib, ponatinib) offer further treatment options.

Purpose of the Study:

• To highlight the emerging cardiovascular toxicities associated with second- and third-generation TKIs used in CML treatment.
• To emphasize the importance of understanding and managing these cardiotoxicities to prevent adverse patient outcomes.
• To underscore the need for collaboration between cardiologists and oncologists in patient care.

Main Methods:

• Review of clinical data and literature concerning TKI-associated cardiotoxicity in CML patients.
• Analysis of reported cardiovascular events linked to specific TKIs.
• Identification of key cardiotoxicities and risk factors.

Main Results:

• Second- and third-generation TKIs are frequently associated with cardiovascular adverse events.
• Major concerns include vascular events (myocardial infarction, stroke, peripheral arterial disease), QT prolongation, pleural effusions, and hypertension.
• These toxicities can limit long-term TKI use and affect patient morbidity and mortality.

Conclusions:

• Cardiovascular toxicities are a significant consideration in patients receiving advanced TKIs for CML.
• Proactive monitoring and risk mitigation strategies are essential for managing these side effects.
• Multidisciplinary collaboration between oncology and cardiology is vital for optimizing patient care and treatment adherence.